ato-oxy

Phase 3Small molecule

UUniversity of Arizona

ato-oxy is one of 3 small molecule programs targeting Obstructive Sleep Apnea (OSA). It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Obstructive Sleep Apnea (OSA)Recruiting

Obstructive Sleep Apnea (OSA)Phase 3

Recruiting

Competition

Competitive Landscape

3 competitors in Obstructive Sleep Apnea (OSA)

#DrugCompanyPhaseTrials

Hdm1005

HHangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

Phase 3

2 2

ato-oxy

UUniversity of Arizona

Phase 3

1 3

Quviviq

Idorsia Pharmaceuticals Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2030

ApprovedRecruiting

Obstructive Sleep Apnea (OSA)

NCT07280468

Clinical

Trials by Indication[1]

Obstructive Sleep Apnea (OSA)1 trial

Endotype DIrected Treatment for OSA in Down Syndrome

Recruiting·UUniversity of Arizona·Approved·NCT07280468·200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ato-oxy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ato-oxy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ato-oxy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Arizona company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity of Arizona

ato-oxy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2030

Trials by Indication[1]

Obstructive Sleep Apnea (OSA)1 trial

References

Drug Info

Quick Facts

Related News